B E Immuno Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 22-06-2024
- Paid Up Capital ₹ 0.10 M
as on 22-06-2024
- Company Age 25 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Satisfied Charges ₹ 1.89 M
as on 22-06-2024
- Revenue 8.57%
(FY 2022)
- Profit -314.53%
(FY 2022)
- Ebitda -148.30%
(FY 2022)
- Net Worth -12.43%
(FY 2022)
- Total Assets 90.03%
(FY 2022)
About B E Immuno Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.10 M.
The company has closed loans amounting to ₹1.89 M, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Mahima Datla, Mantena Purnima, and Sridhar Raju serve as directors at the Company.
- CIN/LLPIN
U24230TG1999PTC031761
- Company No.
031761
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
24 May 1999
- Date of AGM
25 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at B E Immuno Sciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mahima Datla  | Director | 24-May-1999 | Current |
| Mantena Purnima | Additional Director | 12-Apr-2013 | Current |
| Sridhar Raju | Director | 24-May-1999 | Current |
Financial Performance and Corporate Structure Insights of B E Immuno Sciences.
B E Immuno Sciences Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 8.57% increase. The company also saw a substantial fall in profitability, with a 314.53% decrease in profit. The company's net worth observed a substantial decline by a decrease of 12.43%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of B E Immuno Sciences?
In 2021, B E Immuno Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
- Vaxenic India Private LimitedActive 9 years 10 months
Mahima Datla and Mantena Purnima are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Panjab National Bank Creation Date: 25 Nov 2011 | ₹1.89 M | Satisfied |
How Many Employees Work at B E Immuno Sciences?
Unlock and access historical data on people associated with B E Immuno Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of B E Immuno Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped B E Immuno Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
